Clinical Trial Update: Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors [Phase 1]

View source ↗

Summary

Phase 1 study of AZD6422 in CLDN18.2-positive gastrointestinal tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer

Drugs mentioned

• AZD6422

Snippet

Sponsor: Peking University | Conditions: Gastrointestinal Tumors | Phase 1 | Status: COMPLETED